Related references
Note: Only part of the references are listed.Structure and Function of Human Matrix Metalloproteinases
Helena Laronha et al.
CELLS (2020)
Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics
Maryam Raeeszadeh-Sarmazdeh et al.
CELLS (2020)
The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases
Griselda A. Cabral-Pacheco et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases
Gregg B. Fields
FRONTIERS IN IMMUNOLOGY (2019)
Discovery of Novel Soluble Epoxide Hydrolase Inhibitors as Potent Vasodilators
Neetika Tripathi et al.
SCIENTIFIC REPORTS (2018)
Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs
Agata Jablonska-Trypuc et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2016)
The Role of Cytochrome P450 Epoxygenases, Soluble Epoxide Hydrolase, and Epoxyeicosatrienoic Acids in Metabolic Diseases
Xizhen Xu et al.
ADVANCES IN NUTRITION (2016)
Chronic Arachidonic Acid Administration Decreases Docosahexaenoic Acid- and Eicosapentaenoic Acid-Derived Metabolites in Kidneys of Aged Rats
Masanori Katakura et al.
PLOS ONE (2015)
Matrix Metalloproteinases are Involved in Cardiovascular Diseases
Aline Azevedo et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2014)
Is there new hope for therapeutic matrix metalloproteinase inhibition?
Roosmarijn E. Vandenbroucke et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Vasodilatory effect of 14,15-epoxyeicosatrienoic acid on mesenteric arteries in hypertensive and aged rats
Cui Yang et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2014)
The extracellular matrix: Structure, composition, age-related differences, tools for analysis and applications for tissue engineering
Jaspreet K. Kular et al.
JOURNAL OF TISSUE ENGINEERING (2014)
Determination of the Dominant Arachidonic Acid Cytochrome P450 Monooxygenases in Rat Heart, Lung, Kidney, and Liver: Protein Expression and Metabolite Kinetics
Ahmed A. El-Sherbeni et al.
AAPS JOURNAL (2013)
Impact of Soluble Epoxide Hydrolase and Epoxyeicosanoids on Human Health
Christophe Morisseau et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 53, 2013 (2013)
Inhibitory effects of caspase inhibitors on the activity of matrix metalloproteinase-2
M. M. Castro et al.
BIOCHEMICAL PHARMACOLOGY (2013)
In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor
Patricia L. Podolin et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2013)
Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys
A. Ulu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Epoxyeicosatrienoic acids: a double-edged sword in cardiovascular diseases and cancer
Dingzhi Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Discovery of Inhibitors of Soluble Epoxide Hydrolase: A Target with Multiple Potential Therapeutic Indications
Hong C. Shen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Probing Ligand-Binding Modes and Binding Mechanisms of Benzoxazole-Based Amide Inhibitors with Soluble Epoxide Hydrolase by Molecular Docking and Molecular Dynamics Simulation
Hang Chen et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2012)
EPOXIDES AND SOLUBLE EPOXIDE HYDROLASE IN CARDIOVASCULAR PHYSIOLOGY
John D. Imig
PHYSIOLOGICAL REVIEWS (2012)
Matrix metalloproteinase inhibitor properties of tetracyclines: Therapeutic potential in cardiovascular diseases
Michele M. Castro et al.
PHARMACOLOGICAL RESEARCH (2011)
Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs
Hsing-Ju Tsai et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
Incorporation of Piperazino Functionality into 1,3-Disubstituted Urea as the Tertiary Pharmacophore Affording Potent Inhibitors of Soluble Epoxide Hydrolase with Improved Pharmacokinetic Properties
Shao-Xu Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Structure-Based Optimization of Arylamides as Inhibitors of Soluble Epoxide Hydrolase
Anne B. Eldrup et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats
Yuuki Ro et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)
Orally bioavailable potent soluble epoxide hydrolase inhibitors
Sung Hee Hwang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Insight into the structural determinants for selective inhibition of matrix metalloproteinases
Bernard Pirard
DRUG DISCOVERY TODAY (2007)
Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases
Jialiang Hu et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Recent advances in MMP inhibitor design
JF Fisher et al.
CANCER AND METASTASIS REVIEWS (2006)
Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility
IH Kim et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Structural refinement of inhibitors of urea-based soluble epoxide hydrolases
C Morisseau et al.
BIOCHEMICAL PHARMACOLOGY (2002)
Carbonic anhydrase and matrix metalloproteinase inhibitors:: Sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes
A Scozzafava et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
